A panelist discusses how to sequence the four approved cGVHD agents based on patient-specific factors, recommending axatilimab or belumosidil for lung involvement, any of the three oral agents for skin/joint disease, and ibrutinib for lymphoma patients, while considering individual toxicity profiles and disease manifestations.
An expert discusses how combining androgen receptor pathway inhibitors (ARPIs) with PARP inhibitors, particularly enzalutamide with talazoparib, has significantly improved outcomes in metastatic castration-resistant prostate cancer (mCRPC)—especially for patients with homologous recombination repair (HRR) mutations—underscoring the importance of early genomic testing and personalized combination therapy.
An expert discusses how treatment decisions in metastatic castration-resistant prostate cancer (mCRPC) increasingly depend on prior androgen receptor pathway inhibitor (ARPI) exposure, highlighting the need for individualized therapy sequencing based on evolving practice patterns and patient history.
Panelists discuss how future directions in chronic graft-vs-host disease (cGVHD) management may include preemptive use of targeted therapies, first-line treatment with newer agents, and cell-based approaches.
Panelists discuss how axatilimab demonstrates particularly good responses for gastrointestinal graft-vs-host disease (GVHD) and may improve sclerotic skin changes despite lower rates of overall skin response.
Panelists discuss how axatilimab showed promising response rates in the AGAVE-201 trial, even in patients with graft-vs-host disease (cGVHD) who had failed other approved therapies.
An expert shares clinical pearls with the community, offering insights and tips for managing patients effectively.
An expert discusses the safety profiles of combination regimens, effective strategies for managing side effects, and how to weigh the potential for toxicity versus efficacy/benefits when discussing treatment options with patients.
An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and FLAURA2, and shares their impression of icPFS and DoR from MARIPOSA, along with how to determine which patients are best suited for either combination treatment option.
An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their practice.
An expert discusses recent updates on first-line treatments in EGFR-mutated NSCLC, including the MARIPOSA trial comparing amivantamab + lazertinib vs osimertinib, and the FLAURA2 trial of osimertinib + chemotherapy, and how the data is likely to impact the treatment landscape.
An expert discusses the case of a 55-year-old man with EGFR-mutated advanced/metastatic NSCLC, focusing on treatment considerations and management strategies.
A panelist discusses how four FDA-approved agents treat steroid-refractory cGVHD, including ibrutinib (65% response rate), belumosidil (74% response rate), ruxolitinib (50% vs 25% in phase 3 trial), and axatilimab (74% response rate with durable responses lasting 17.2 months median failure-free survival).
Panelists discuss how new treatments like rusfertide (a hepcidin mimetic) offer promising options for polycythemia vera patients, demonstrating benefits in reducing phlebotomy requirements while addressing the paradoxical iron deficiency caused by current treatments, potentially improving quality of life while allowing patients to maintain their existing cytoreductive therapies, though questions remain about whether it will show the disease-modifying effects seen with ruxolitinib and interferons.
Panelists discuss how interferon therapy for polycythemia vera requires patient education about its unique characteristics, including the need for long-term treatment (with benefits most apparent at 36 months rather than 12 months), potential adverse effects (mild flu-like symptoms, depression, injection site reactions, and autoimmune issues), and evolving dosing strategies that may improve tolerability, while emphasizing that with FDA approval of ropeginterferon, insurance hurdles have decreased and molecular response monitoring may eventually guide treatment optimization.
A panelist discusses how advances in chronic graft-vs-host disease (cGVHD) prevention include posttransplant cyclophosphamide showing significant reduction in moderate to severe cGVHD and the promising Precision-T trial using split-dose infusions of regulatory T cells followed by conventional T cells, both demonstrating improved cGVHD-free survival compared with standard prophylaxis.
A panelist discusses how community-based care coordination can be implemented for patients with chronic graft-vs-host disease (cGVHD) on axatilimab, with initial cycles administered at specialized centers followed by local infusions under community oncologist supervision, with periodic assessment visits to evaluate treatment response.
Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant.
Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.
Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.
Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.
Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations.
Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.
Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for patients with hormone receptor-positive metastatic breast cancer.
Panelists discuss how belumosudil is particularly effective for patients with lung involvement due to its antifibrotic mechanism.
Panelists discuss how clinicians typically taper steroids slowly after starting second-line agents for chronic graft-vs-host disease (cGVHD).
Panelists discuss how the MAJIC-PV trial provides critical evidence that ruxolitinib offers more than symptomatic relief in polycythemia vera, demonstrating approximately 40% reduction in thromboembolic events and improved event-free survival while correlating these clinical benefits with molecular responses through JAK2 V617F allele burden reduction, suggesting ruxolitinib may be truly disease-modifying rather than merely a bandage treatment when comprehensive control of all 3 blood cell lineages (red cells, white cells, and platelets) is achieved.
A panelist discusses how treatment sequencing for neuroendocrine tumors (NETs) is less important than ensuring patients receive all available treatments, highlighting cabozantinib as a reasonable second- or third-line option with manageable adverse effects like hypertension and liver function abnormalities.
A panelist discusses how NCCN guidelines now include cabozantinib as a category 1 recommendation for gastrointestinal (GI) neuroendocrine tumors (NETs) after prior treatment with everolimus or lutetium-177 dotatate, with slightly different recommendations for pancreatic, lung, and thymic NETs.
Panelists discuss how ruxolitinib provides comprehensive benefits for polycythemia vera patients beyond count control, highlighting its remarkable ability to rapidly alleviate severe pruritus (often within 48 hours) and other constitutional symptoms that remain resistant to conventional therapies like hydroxyurea and interferon while also effectively managing cytokine-driven and spleen-related symptoms that significantly impact quality of life.